ライフサイエンスコーパス: Kaposi sarcoma

1 therapy for extensive or treatment-resistant Kaposi sarcoma.

2 nd phosphorylated RelA was observed in human Kaposi sarcoma.

3 nd 96.3% (77/80) among control patients with Kaposi sarcoma.

4 Human herpesvirus 8 (HHV-8) causes Kaposi sarcoma.

5 ole for this molecule in the pathogenesis of Kaposi sarcoma.

6 8 as a potential novel therapeutic avenue in Kaposi sarcoma.

7 with acquired immune deficiency syndrome and Kaposi sarcoma.

8 ty has been found to exceed the incidence of Kaposi sarcoma.

9 posed as options in the future management of Kaposi sarcoma.

10 emodialysis, and iron) in the development of Kaposi sarcoma.

11 ents might increase the risk and severity of Kaposi sarcoma.

12 ssociated with the endothelial-derived tumor Kaposi sarcoma.

13 posttransplant period, one of whom developed Kaposi sarcoma.

14 metabolic complications, frequently develop Kaposi sarcoma.

15 -OIs were Pneumocystis pneumonia (39.1%) and Kaposi sarcoma (20.1%).

16 without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.

17 cell carcinoma of the skin were found after Kaposi sarcoma (685.68) and Merkel cell carcinoma (117.2

18 e advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.

19 timal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and

20 first to demonstrate that Axl is induced in Kaposi sarcoma and Kaposi sarcoma herpesvirus (KSHV) tra

21 gnancies except for specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

22 ay result in lower expression of TbetaRII in Kaposi sarcoma and multicentric Castleman disease.

23 tive incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

24 application as a new treatment modality for Kaposi sarcoma and other cancers of endothelial origin.

25 genic virus that promotes the development of Kaposi sarcoma and other malignancies that occur in pati

26 upregulation both in vitro and in vivo, and Kaposi sarcoma and primary effusion lymphoma cells demon

27 K1 protein is expressed in Kaposi sarcoma and primary effusion lymphoma.

28 (KSHV) is linked with all clinical forms of Kaposi sarcoma and several lymphoproliferative disorders

29 gen and is the causative infectious agent of Kaposi sarcoma and two malignancies of B cell origin.

30 elated to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, melanoma, thyr

31 PTLD, Kaposi sarcoma, and lung and bronchial cancers were incr

32 nvasive and in situ squamous cell carcinoma, Kaposi sarcoma, and Merkel cell carcinoma.

33 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative d

34 rcoma, epithelioid hemangioendothelioma, and Kaposi sarcoma are classified according to the line of d

35 ression microarrays that neoplastic cells of Kaposi sarcoma are closely related to lymphatic endothel

36 Consequently, KSHV-infected tumor cells in Kaposi sarcoma are poorly differentiated endothelial cel

37 ART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstituti

38 Kaposi sarcoma-associated (KS-associated) herpesvirus (K

39 homa cells infected by Epstein-Barr virus or Kaposi sarcoma-associated herpes virus (KSHV) are exquis

40 Kaposi sarcoma-associated herpes virus (KSHV) encodes a

41 ng protein (vFLIP), encoded by the oncogenic Kaposi sarcoma-associated herpes virus (KSHV), constitut

42 odgkin lymphoma associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).

43 Human herpes virus 8 (HHV-8) or Kaposi sarcoma-associated herpes virus is the etiologic

44 invariably associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV or HHV8).

45 que rhadinovirus (RRV) is closely related to Kaposi sarcoma-associated herpesvirus (KSHV) and is asso

46 Kaposi sarcoma is caused by infection of Kaposi sarcoma-associated herpesvirus (KSHV) and is char

47 A-binding domains (DBDs), LANA homologs from Kaposi sarcoma-associated herpesvirus (KSHV) and MHV68 e

48 ion that is transferable to MHV68.IMPORTANCE Kaposi sarcoma-associated herpesvirus (KSHV) and murine

49 s subfamily of gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV) and murine

50 In Sub-Saharan Africa, where HIV and the Kaposi sarcoma-associated herpesvirus (KSHV) are endemic

51 Kaposi sarcoma-associated herpesvirus (KSHV) can establi

52 Open reading frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus (KSHV) causes sust

53 T-cell immunity is important for controlling Kaposi sarcoma-associated herpesvirus (KSHV) diseases su

54 Among 233 children, Kaposi sarcoma-associated herpesvirus (KSHV) DNA was det

55 Kaposi sarcoma-associated herpesvirus (KSHV) encodes 12

56 The K1 gene of Kaposi sarcoma-associated herpesvirus (KSHV) encodes a t

57 n tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish p

58 Kaposi sarcoma-associated herpesvirus (KSHV) has a causa

59 Kaposi sarcoma-associated herpesvirus (KSHV) has been id

60 The Kaposi sarcoma-associated herpesvirus (KSHV) has been li

61 , a multifunctional protein expressed by the Kaposi sarcoma-associated herpesvirus (KSHV) in latently

62 Kaposi sarcoma-associated herpesvirus (KSHV) infection i

63 Kaposi sarcoma-associated herpesvirus (KSHV) infection i

64 The cellular reservoir for Kaposi sarcoma-associated herpesvirus (KSHV) infection i

65 Recent reports link Kaposi sarcoma-associated herpesvirus (KSHV) infection o

66 To develop an animal model of Kaposi sarcoma-associated herpesvirus (KSHV) infection u

67 e of the JCI, Ganem and colleagues show that Kaposi sarcoma-associated herpesvirus (KSHV) inhibits CD

68 Kaposi sarcoma-associated herpesvirus (KSHV) is a B-lymp

69 Kaposi sarcoma-associated herpesvirus (KSHV) is a human

70 Kaposi sarcoma-associated herpesvirus (KSHV) is a human

71 Kaposi sarcoma-associated herpesvirus (KSHV) is a member

72 Kaposi sarcoma-associated herpesvirus (KSHV) is an emerg

73 ically, the thymidine kinase (TK) encoded by Kaposi sarcoma-associated herpesvirus (KSHV) is an extre

74 Kaposi sarcoma-associated herpesvirus (KSHV) is an oncog

75 Kaposi sarcoma-associated herpesvirus (KSHV) is associat

76 Kaposi sarcoma-associated herpesvirus (KSHV) is consiste

77 Kaposi sarcoma-associated herpesvirus (KSHV) is etiologi

78 The oncogenic gammaherpesvirus Kaposi sarcoma-associated herpesvirus (KSHV) is globally

79 Kaposi sarcoma-associated herpesvirus (KSHV) is linked w

80 Kaposi sarcoma-associated herpesvirus (KSHV) is necessar

81 Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is now know

82 To assess the role of IL-6 in Kaposi sarcoma-associated herpesvirus (KSHV) latency, KS

83 The Kaposi sarcoma-associated herpesvirus (KSHV) latency-ass

84 ng of genes believed to be essential for the Kaposi sarcoma-associated herpesvirus (KSHV) latent life

85 Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a

86 Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a

87 show that the lytic replication cycle of the Kaposi sarcoma-associated herpesvirus (KSHV) promotes do

88 Kaposi sarcoma-associated herpesvirus (KSHV) stimulates

89 at treatment of cells latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) with glycyr

90 However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endem

91 Kaposi sarcoma-associated herpesvirus (KSHV), also known

92 Kaposi sarcoma-associated herpesvirus (KSHV), also known

93 associated with epigenetic modifications of Kaposi sarcoma-associated herpesvirus (KSHV), an oncogen

94 Gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV), establish

95 Many viruses, including Kaposi sarcoma-associated herpesvirus (KSHV), have evolv

96 Kaposi sarcoma-associated herpesvirus (KSHV), one of the

97 Cellular immune responses to Kaposi sarcoma-associated herpesvirus (KSHV), the etiolo

98 rtant role in early childhood infection with Kaposi sarcoma-associated herpesvirus (KSHV), the matern

99 virus (HIV) type 1-infected subjects without Kaposi sarcoma-associated herpesvirus (KSHV)-associated

100 We recently identified polymorphisms in Kaposi sarcoma-associated herpesvirus (KSHV)-encoded mic

101 Moreover, Kaposi sarcoma-associated herpesvirus (KSHV)-encoded vir

102 We report that A20 is expressed in Kaposi sarcoma-associated herpesvirus (KSHV)-infected pr

103 All PELs carry Kaposi sarcoma-associated herpesvirus (KSHV).

104 virus-positive individuals and is caused by Kaposi sarcoma-associated herpesvirus (KSHV).

105 firmed in the TR and viral Bcl-2 promoter of Kaposi sarcoma-associated herpesvirus (KSHV).

106 a and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV).

107 rcoma, which is caused by infection with the Kaposi sarcoma-associated herpesvirus (KSHV).

108 ion lymphoma (PEL) cases are associated with Kaposi sarcoma-associated herpesvirus (KSHV).

109 The seroprevalence of Kaposi sarcoma-associated herpesvirus (KSHV)/human herpe

110 Kaposi sarcoma-associated herpesvirus (KSHV; also known

111 The Kaposi sarcoma-associated herpesvirus (KSHV; or human he

112 V4), cytomegalovirus (HHV5), HHV6, HHV7, and Kaposi sarcoma-associated herpesvirus (termed KSV or HHV

113 ) to infection by a novel human herpesvirus (Kaposi sarcoma-associated herpesvirus [KSHV]) is one of

114 -like inhibitory protein (FLIP) protein from Kaposi sarcoma-associated herpesvirus activates the NF-k

115 hundred percent of PELs carry the genome of Kaposi sarcoma-associated herpesvirus and a majority are

116 The oncogenic gamma-herpesviruses EBV and Kaposi sarcoma-associated herpesvirus are ubiquitous hum

117 an gammaherpesviruses Epstein-Barr virus and Kaposi Sarcoma-associated herpesvirus both contain a gly

118 Kaposi sarcoma-associated herpesvirus GPCR (kGPCR) activ

119 other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the ge

120 ly that the open reading frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90

121 sion of the viral interleukin-6 homolog from Kaposi sarcoma-associated herpesvirus is also sufficient

122 Kaposi sarcoma-associated herpesvirus is the causative a

123 We found that Kaposi sarcoma-associated herpesvirus K12-1 miRNA (23 ba

124 tiated blood vascular endothelial cells with Kaposi sarcoma-associated herpesvirus leads to their lym

125 o the sustained activation of ERK and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.

126 lity complex class I in cells expressing the Kaposi sarcoma-associated herpesvirus protein K3, is una

127 This family includes Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus, human pathogens a

128 n gamma-2 herpesvirus closely related to the Kaposi sarcoma-associated herpesvirus, replicates lytica

129 and endothelial cells latently infected with Kaposi sarcoma-associated herpesvirus, suggesting that a

130 Kaposi sarcoma-associated herpesvirus-encoded interleuki

131 uch as HIV, Epstein-Barr virus, malaria, and Kaposi sarcoma-associated herpesvirus.

132 Effects of Ca-SP on Kaposi sarcoma-associated herpesvirus/human herpes virus

133 Ca-SP also inhibited entry of Kaposi sarcoma-associated herpesvirus/human herpes virus

134 Kaposi sarcoma-associated herpesvirus/human herpesvirus

135 Kaposi sarcoma-associated herpesvirus/human herpesvirus

136 We cloned ten miRNAs in the Kaposi sarcoma-associated virus (KSHV or HHV8), nine miR

137 The human gamma herpesviruses, Kaposi sarcoma-associated virus (KSHV) and EBV, are asso

138 with HIV and advanced stage AIDS-associated Kaposi sarcoma attending 11 AIDS Clinical Trials Group s

139 ciated herpesvirus (KSHV) has been linked to Kaposi sarcoma, body cavity-based lymphoma, and Castlema

140 virus type 1 (HIV-1) infection and risk for Kaposi sarcoma, but behaviors associated with HHV-8 tran

141 a suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as

142 However, in some Kaposi sarcoma cells, KSHV undergoes a productive life c

143 traditional AIDS-defining cancers, including Kaposi sarcoma, cervical cancer, and non-Hodgkin lymphom

144 Classic Kaposi sarcoma (cKS) is an inflammatory tumor caused by

145 ous conditions such as hepatitis C, but also Kaposi sarcoma, clustered significantly, suggesting tran

146 how that mTOR inhibitors exert a direct anti-Kaposi sarcoma effect by inhibiting angiogenesis and par

147 Human herpesvirus 8, which causes Kaposi sarcoma, expresses the MARCH family ubiquitin lig

148 orably alter the clinical characteristics of Kaposi sarcoma favorably, they seem not to alter the nat

149 the virus promotes tumorigenesis leading to Kaposi sarcoma formation.

150 a new diagnostic tool to help differentiate Kaposi sarcoma from its mimics.

151 ppears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associa

152 Also, a new staging system for classic Kaposi sarcoma has been proposed.

153 assification system for staging AIDS-related Kaposi sarcoma has been refined.

154 Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence i

155 y endothelial transformation mediated by the Kaposi sarcoma herpes virus (KSHV)-encoded G-protein-cou

156 Kaposi sarcoma herpesvirus (KSHV) induces transcriptiona

157 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus (KSHV) infection and is thoug

158 tion of miR-30b or miR-30c expression during Kaposi sarcoma herpesvirus (KSHV) infection attenuated v

159 lymphatic endothelial cells (LECs) and that Kaposi sarcoma herpesvirus (KSHV) infects both LECs and

160 ren with Kaposi sarcoma who met criteria for Kaposi sarcoma herpesvirus (KSHV) inflammatory cytokine

161 latency-associated nuclear antigen (LANA) of Kaposi sarcoma herpesvirus (KSHV) is mainly localized an

162 Kaposi sarcoma herpesvirus (KSHV) is specifically associ

163 Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi

164 Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent

165 Kaposi sarcoma herpesvirus (KSHV) is the most common cau

166 emonstrate that RelA/NF-kappaB activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP

167 PURPOSE OF REVIEW: The discovery of Kaposi sarcoma herpesvirus (KSHV) led to recognition of

168 he transmembrane ubiquitin ligase K5/MIR2 of Kaposi sarcoma herpesvirus (KSHV) mediates internalizati

169 Kaposi sarcoma herpesvirus (KSHV) persists as a latent n

170 sttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/

171 te that Axl is induced in Kaposi sarcoma and Kaposi sarcoma herpesvirus (KSHV) transformed endothelia

172 Kaposi sarcoma herpesvirus (KSHV), a human gammaherpesvi

173 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

174 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

175 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

176 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

177 We show that this pathway is blocked in Kaposi sarcoma herpesvirus (KSHV)-infected primary effus

178 Kaposi sarcoma herpesvirus is found in the monotypic pol

179 Amino acid substitutions in Kaposi sarcoma herpesvirus LANA and prototype foamy viru

180 Peptides studied included segments of Kaposi sarcoma herpesvirus latency-associated nuclear an

181 al interferon regulatory factor 1 (vIRF1), a Kaposi sarcoma herpesvirus protein, destabilizes p53 by

182 We studied the presence of Kaposi sarcoma herpesvirus sequences in cell-free DNA (c

183 by human herpesvirus 8 (HHV8, also known as Kaposi sarcoma herpesvirus).

184 imate herpesviruses, including the oncogenic Kaposi sarcoma herpesvirus, encode cyclin D homologues.

185 ar analysis of the cellular cyclin D and the Kaposi sarcoma herpesvirus-cyclin to delineate the molec

186 Worldwide Kaposi sarcoma herpesvirus/human herpesvirus 8 (HHV8) se

187 revealed 3 distinct HHV-8-related entities: Kaposi sarcoma, HHV-8-associated multicentric Castleman

188 ART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART wit

189 its use in treating advanced AIDS-associated Kaposi sarcoma in resource-limited settings.

190 elines for the most effective treatments for Kaposi sarcoma in SSA.

191 o highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment.

192 In our study, Kaposi sarcoma in transplanted patients with HIV did not

193 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpe

194 Kaposi sarcoma is a vascular tumor related to herpesviru

195 Kaposi sarcoma is caused by infection of Kaposi sarcoma-

196 The biology of Kaposi sarcoma is poorly understood because the dominant

197 Kaposi sarcoma is the most common cancer in human immuno

198 a-associated herpesvirus (KSHV) are endemic, Kaposi sarcoma is the most common cancer overall, but mo

199 Kaposi sarcoma is the most common human herpesvirus 8 (H

200 virus (KSHV) is specifically associated with Kaposi sarcoma (KS) and 2 B cell lymphoproliferative dis

201 tiological agent for the endothelial-derived Kaposi sarcoma (KS) and also for certain lymphoprolifera

202 Incidence rates for Kaposi sarcoma (KS) and lymphomas were highest in the fi

203 pesvirus 8 (HHV-8) is the causative agent of Kaposi sarcoma (KS) and multicentric Castleman disease (

204 from the blood of patients with AIDS-related Kaposi sarcoma (KS) and primary effusion lymphoma (PEL).

205 Kaposi sarcoma (KS) can develop following organ transpla

206 Ten Kaposi sarcoma (KS) exacerbations and 1 newly diagnosed

207 Kaposi sarcoma (KS) gained public attention as an AIDS-d

208 Kaposi sarcoma (KS) had the highest IR (634.7 per 100 00

209 Kaposi sarcoma (KS) herpesvirus-associated multicentric

210 The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV

211 The high frequency of Kaposi sarcoma (KS) in immunodeficiency states, particul

212 Kaposi sarcoma (KS) incidence has decreased since combin

213 Kaposi sarcoma (KS) is a complication of KS-associated h

214 Kaposi sarcoma (KS) is a multifocal angioproliferative n

215 Kaposi sarcoma (KS) is an angioproliferative tumor deriv

216 Kaposi sarcoma (KS) is associated with human herpesvirus

217 Kaposi sarcoma (KS) is associated with KS-associated her

218 Classic Kaposi sarcoma (KS) is exceedingly rare in children from

219 Kaposi sarcoma (KS) is primarily caused by human herpesv

220 Recent studies have suggested that Kaposi sarcoma (KS) rates might be increasing in some ra

221 Kaposi sarcoma (KS) remains a frequent cancer in human i

222 Kaposi sarcoma (KS) remains the most common AIDS-associa

223 Thirty-six patients with AIDS-associated Kaposi sarcoma (KS) requiring chemotherapy were treated

224 We compared Kaposi sarcoma (KS) risk in adults who started antiretro

225 Kaposi sarcoma (KS) risk is affected by perturbed immuni

226 d clinical manifestations notably range from Kaposi sarcoma (KS) to either primary effusion lymphoma

227 The linkage of Kaposi sarcoma (KS) to infection by a novel human herpes

228 n, angiogenesis, and inflammation to promote Kaposi sarcoma (KS) tumor growth, which involves various

229 red immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) whose KS was progressing while on an

230 Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in hu

231 Kaposi sarcoma (KS), a human herpes virus 8 (HHV-8; also

232 Kaposi sarcoma (KS), a multifocal neoplasm of the skin t

233 erpesvirus (KSHV) is etiologically linked to Kaposi sarcoma (KS), a tumor genetically akin to lymphat

234 rus and the culprit behind the human disease Kaposi sarcoma (KS), an AIDS-defining malignancy.

235 man herpesvirus 8, is the etiologic agent of Kaposi sarcoma (KS), an angioproliferative lesion charac

236 ed in primary effusion lymphoma (PEL) and in Kaposi sarcoma (KS), an endothelial cell tumor.

237 ecimens of 11 HIV-related, 7 non-HIV-related Kaposi sarcoma (KS), and 7 normal skin tissues (NSTs) of

238 k of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs

239 herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS), one of the leading cancers in human

240 ical agent of three different human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and

241 erpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

242 erpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

243 s of the microRNA-coding region of KSHV from Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

244 us 8 (KSHV/HHV-8) is etiologically linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

245 i sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

246 ociated with 3 different human malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and mult

247 likely to play a pivotal role in controlling Kaposi sarcoma (KS)-associated herpesvirus (KSHV) and pr

248 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) encode

249 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) is eti

250 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) subtyp

251 lovir, a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in cl

252 Antibody responses against lytic and latent Kaposi sarcoma (KS)-associated herpesvirus antigens were

253 Epidemiological studies of Kaposi sarcoma (KS)-related herpesvirus (KSHV) indicate

254 infection is essential to the development of Kaposi sarcoma (KS).

255 as been identified as the etiologic agent of Kaposi sarcoma (KS).

256 a (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%).

257 idence of the 3 AIDS-defining cancers (ADCs; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cer

258 Kaposi sarcoma lesional cells, now confirmed to be of ly

259 ate expression of the KSHV-encoded miRNAs in Kaposi sarcoma lesions and demonstrate that these miRNAs

260 The detection of HHV8 in Kaposi sarcoma lesions has provided a new diagnostic too

261 In the transplant setting, Kaposi sarcoma lesions have been shown to originate from

262 understood because the dominant cell type in Kaposi sarcoma lesions is not known.

263 n KSHV-infected spindle tumor cells in human Kaposi sarcoma lesions.

264 n expression was drastically up-regulated in Kaposi sarcoma-like lesions and that loss of IKKepsilon

265 nd was treated with the usual posttransplant Kaposi sarcoma management protocol.

266 gh cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer su

267 Kaposi sarcoma occurred during the first year after tran

268 ce of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin.

269 ases such as the endothelial cell malignancy Kaposi sarcoma, or the B-cell malignancy, primary effusi

270 Kaposi sarcoma originates from endothelial cells and it

271 e tumor cells of endemic and AIDS-associated Kaposi sarcoma, primary effusion lymphoma, and Castleman

272 esvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicent

273 iated herpes virus is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma ce

274 critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some case

275 transfected BJAB lymphoma, THP-1, U937, and Kaposi sarcoma SLK cells to express K1 and a K1 mutant w

276 the epidemiology, biology, and management of Kaposi sarcoma that was published in the last year.

277 Unlike Kaposi sarcoma, the incidence does not correlate with CD

278 Kaposi sarcoma, the most common cancer in HIV-positive i

279 d literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignanc

280 de prognostic information about AIDS-related Kaposi sarcoma, the traditional classification system fo

281 here are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively

282 ved that a small number of latently infected Kaposi sarcoma tumor cells undergo spontaneous lytic rea

283 ssion of lymphatic lineage-specific genes by Kaposi sarcoma tumor cells.

284 e in lymphatic endothelial cells, supporting Kaposi sarcoma tumorigenesis and representing attractive

285 hatic microenvironment is more favorable for Kaposi sarcoma tumorigenesis.

286 Thus, Kaposi sarcoma tumors express numerous lymphatic endothe

287 In Kaposi sarcoma tumors, SOX18 and PROX1 expression correl

288 d mesenchymal stem cells, which give rise to Kaposi sarcoma tumors.

289 High expression of EZH2 was observed in Kaposi sarcoma tumors.

290 vironment supporting persistent infection in Kaposi sarcoma tumors.

291 atabase (19 077 patients), the prevalence of Kaposi sarcoma was 0.18% and 0.46%, respectively, in tra

292 The median time from HIV infection to Kaposi sarcoma was 20 years.

293 ere more common in white OTRs (P < .001) and Kaposi sarcoma was more common in black OTRs (P < .001).

294 Kaposi sarcoma was observed in 9 cases.

295 RECENT FINDINGS: A total of 176 non-Kaposi sarcoma were identified, 75 in people with HIV an

296 infected patients who subsequently developed Kaposi sarcoma were included.

297 sive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a.

298 rt the development of a novel mouse model of Kaposi sarcoma, where KSHV is retained stably and tumors

299 is the most effective therapeutic target of Kaposi sarcoma, which is caused by infection with the Ka

300 ciency virus-infected Malawian children with Kaposi sarcoma who met criteria for Kaposi sarcoma herpe